Seeking AlphaCodex · 实盘不做把握 7/10
北京时间·🕒 发布 22:30:50时区推断·⟳ 抓取 22:36:03·⚡ 决策 07-23 22:37:27 +1m24s·95.8 天前
Quest Diagnostics二季度业绩超预期并上调全年指引
Quest Diagnostics二季度调整后EPS为3.12美元、收入30.4亿美元，均高于市场预期，并上调全年收入和EPS指引。
📄 原文Seeking Alpha↗ 原文
Quest Diagnostics climbs as Q2 earnings top estimates, guidance raised
Quest Diagnostics (DGX) shares climbed about 11% on Thursday after the diagnostic testing company reported second-quart…
不做 Quest Diagnostics（DGX.US）
同一具体财报催化已在本日多次处理为不做，且盘中已约11%同向反应；当前重复转述没有新的可交易增量，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-23 · 扩散 high · price-in 风险 high ↗
关键理由
- Quest Diagnostics二季度调整后EPS为3.12美元、收入30.4亿美元，均高于市场预期，并上调全年收入和EPS指引。
- 但该催化属于财报日明牌披露，且我们案例库显示同一具体催化在本日已多次处理为不做，当前再出卡属于重复。
主要风险
- 美股盘中已对财报和指引上修作出约11%的同向反应，追高的剩余edge不足。
反向证据
- 做多前查反向 · 来源 kb_search · 影响 none
内部KB检索服务连接失败，未能补充旧闻或反向证据；但重复处理和盘中已大幅反应已足以否决本次再交易。
检索:Quest Diagnostics Q2 2026 earnings guidance raised consensus July 2026 - 做多前查反向 · 来源 search_case_library · 日期 2026-07-23 · 影响 weakens
案例库命中多条同一DGX二季度业绩超预期并上调指引的本日不做记录，削弱重复出卡与追单必要性。
检索:DGX.US case library
工具调用 · 历史记录,结果未知(4 种)
- search_processed_events · 结果未知
- normalize_ticker · 结果未知
- kb_search · 结果未知
- search_case_library · 结果未知
原文全文
展开原文 · 826 字
Quest Diagnostics (DGX) shares climbed about 11% on Thursday after the diagnostic testing company reported second-quarter results that topped Wall Street estimates and lifted its full-year 2026 guidance above consensus.
The company posted adjusted earnings of $3.12 per share, beating analysts' expectations by $0.30, while revenue rose 10.1% year over year to $3.04B, exceeding consensus by $70M.
Revenue from the firm’s diagnostic information services surged ~10.3% Y/Y to $2.9B.
Looking ahead, Quest Diagnostics now expects full-year 2026 revenue of $11.95B to $12.05B (prior outlook: $11.78B - $11.90B), above the Street estimate of $11.85B. The company also raised its earnings outlook, forecasting adjusted diluted EPS of $11.05 to $11.25 (vs. $10.63 - $10.83 previously), compared with the consensus estimate of $10.77.
The company posted adjusted earnings of $3.12 per share, beating analysts' expectations by $0.30, while revenue rose 10.1% year over year to $3.04B, exceeding consensus by $70M.
Revenue from the firm’s diagnostic information services surged ~10.3% Y/Y to $2.9B.
Looking ahead, Quest Diagnostics now expects full-year 2026 revenue of $11.95B to $12.05B (prior outlook: $11.78B - $11.90B), above the Street estimate of $11.85B. The company also raised its earnings outlook, forecasting adjusted diluted EPS of $11.05 to $11.25 (vs. $10.63 - $10.83 previously), compared with the consensus estimate of $10.77.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。